PAIN
Volume 141, Issue 1 , Pages 4-5 , January 2009

Improving early clinical drug development for neuropathic pain by improving patient selection

Received 10 November 2008 ,Accepted 10 November 2008.

References 

  1. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain. 2006;122:289–294
  2. Colloca L, Benedetti F. How prior experience shapes placebo analgesia. Pain. 2006;124:126–133
  3. Gruener G, Dyck PJ. Quantitative sensory testing: methodology, applications, and future directions. J Clin Neurophysiol. 1994;11:568–583
  4. Ho TW, Backonja M, Ma J, Leibensperger H, Froman S, Polydefkis M. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain. 2009;141:19–24
  5. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197
  6. Nebuchennykh M, Loseth S, Stalberg E, Mellgren SI. Quantitative sensory testing in patients with polyneuropathy and healthy individuals. Acta Neurol Scand Suppl. 2008;188:56–61
  7. Periquet MI, Novak V, Collins MP, Nagaraja HN, Erdem S, Nash SM, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology. 1999;53:1641–1647
  8. Santiago S, Ferrer T, Espinosa ML. Neurophysiological studies of thin myelinated (A delta) and unmyelinated (C) fibers: application to peripheral neuropathies. Neurophysiol Clin. 2000;30:27–42

PII: S0304-3959(08)00701-X

doi: 10.1016/j.pain.2008.11.003

PAIN
Volume 141, Issue 1 , Pages 4-5 , January 2009

Article Tools